艰难梭菌感染。
Clostridium difficile infection.
机构信息
Departments of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
出版信息
Am J Med Sci. 2010 Sep;340(3):247-52. doi: 10.1097/MAJ.0b013e3181e939d8.
Abstract
Clostridium difficile is the leading cause of hospital-acquired diarrhea in Europe and North America and is a serious reemerging pathogen. Recent outbreaks have led to increasing morbidity and mortality and have been associated with a new strain (BI/NAP1/027) of C difficile that produces more toxin than historic strains. With the increasing incidence of C difficile infection, clinicians have also seen a change in the epidemiology with increased infections in previously low-risk populations. This chapter highlights the current knowledge on C difficile virulence, human disease, epidemic outbreaks and optimal treatment strategies.
摘要
艰难梭菌是欧洲和北美的主要医院获得性腹泻病原体，也是一种严重的重新出现的病原体。最近的疫情爆发导致发病率和死亡率上升，并与艰难梭菌的一种新型菌株（BI/NAP1/027）有关，该菌株产生的毒素比历史菌株多。随着艰难梭菌感染的发病率不断上升，临床医生也发现了流行情况的变化，以前低危人群的感染有所增加。本章重点介绍了艰难梭菌毒力、人类疾病、疫情爆发和最佳治疗策略的最新知识。
相似文献
1
Clostridium difficile infection.艰难梭菌感染。
Am J Med Sci. 2010 Sep;340(3):247-52. doi: 10.1097/MAJ.0b013e3181e939d8.
2
Emergence of an outbreak-associated Clostridium difficile variant with increased virulence.出现一种与暴发相关的、毒力增强的艰难梭菌变体。
J Clin Microbiol. 2015 Apr;53(4):1216-26. doi: 10.1128/JCM.03058-14. Epub 2015 Feb 4.
3
Current status of Clostridium difficile infection epidemiology.艰难梭菌感染流行病学的现状。
Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S65-70. doi: 10.1093/cid/cis319.
4
Clostridium difficile infection: a worldwide disease.艰难梭菌感染：一种全球性疾病。
Gut Liver. 2014 Jan;8(1):1-6. doi: 10.5009/gnl.2014.8.1.1. Epub 2014 Jan 13.
5
The changing epidemiology of Clostridium difficile infections.艰难梭菌感染的流行病学变化。
Clin Microbiol Rev. 2010 Jul;23(3):529-49. doi: 10.1128/CMR.00082-09.
6
An epidemic, toxin gene-variant strain of Clostridium difficile.一种艰难梭菌的流行、毒素基因变异菌株。
N Engl J Med. 2005 Dec 8;353(23):2433-41. doi: 10.1056/NEJMoa051590. Epub 2005 Dec 1.
7
Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.艰难梭菌感染的临床结果、菌株类型与毒力相关表型之间缺乏关联。
J Clin Microbiol. 2011 Dec;49(12):4040-6. doi: 10.1128/JCM.05053-11. Epub 2011 Sep 28.
8
infection in the Asia-Pacific region.亚太地区的感染情况。
Emerg Microbes Infect. 2019 Dec 24;9(1):42-52. doi: 10.1080/22221751.2019.1702480. eCollection 2020.
9
Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection.评估 Xpert 艰难梭菌检测法在艰难梭菌感染诊断中的应用。
Ann Lab Med. 2012 Sep;32(5):355-8. doi: 10.3343/alm.2012.32.5.355. Epub 2012 Aug 13.
10
Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.艰难梭菌感染的诊断：临床医生和临床实验室面临的持续难题。
Clin Microbiol Rev. 2013 Jul;26(3):604-30. doi: 10.1128/CMR.00016-13.
引用本文的文献
1
Lipidomics, Microbiota, and Intestinal Infection Outcome.脂质组学、微生物群与肠道感染结果
Int J Mol Sci. 2025 Aug 24;26(17):8214. doi: 10.3390/ijms26178214.
2
Can Gut Microbiota Analysis Reveal Infection? Evidence from an Italian Cohort at Disease Onset.肠道微生物群分析能否揭示感染？来自意大利一个疾病发作队列的证据。
Microorganisms. 2024 Dec 25;13(1):16. doi: 10.3390/microorganisms13010016.
3
A Three-Year Analysis of Mortality in Clostridioides difficile Patients in a Tertiary Center.三级医疗中心艰难梭菌感染患者死亡率的三年分析
Cureus. 2024 Nov 23;16(11):e74291. doi: 10.7759/cureus.74291. eCollection 2024 Nov.
4
MicroRNA miR-27a-5p Reduces Intestinal Inflammation Induced by Clostridioides difficile Flagella by Regulating the Nuclear Factor-κB Signaling Pathway.微小RNA miR-27a-5p通过调节核因子κB信号通路减轻艰难梭菌鞭毛诱导的肠道炎症
J Infect Dis. 2025 Feb 4;231(1):e38-e46. doi: 10.1093/infdis/jiae396.
5
Phenylthiazoles with potent & optimum selectivity toward .对……具有强效且最佳选择性的苯并噻唑。
RSC Med Chem. 2024 Mar 22;15(6):1991-2001. doi: 10.1039/d4md00164h. eCollection 2024 Jun 19.
6
[Analysis of infection characteristics and risk factors in patients hospitalized for diarrhea in 3 university hospitals in a mid-south city of China].[中国中南部某城市3家大学医院腹泻住院患者感染特征及危险因素分析]
Nan Fang Yi Ke Da Xue Xue Bao. 2024 May 20;44(5):998-1003. doi: 10.12122/j.issn.1673-4254.2024.05.23.
7
Clostridioides (Clostridium) difficile: A silent nosocomial pathogen.艰难梭菌（梭状芽孢杆菌）：一种沉默的医院病原体。
Saudi Med J. 2023 Sep;44(9):825-835. doi: 10.15537/smj.2023.44.9.20230216.
8
The Environment, Farm Animals and Foods as Sources of Infection in Humans.作为人类感染源的环境、农场动物和食物。
Foods. 2023 Mar 4;12(5):1094. doi: 10.3390/foods12051094.
9
infection: traversing host-pathogen interactions in the gut.感染：穿越肠道中的宿主-病原体相互作用。
Microbiology (Reading). 2023 Feb;169(2). doi: 10.1099/mic.0.001306.
10
Comparison between Symptomatic and Asymptomatic Mice after Infection Reveals Novel Inflammatory Pathways and Contributing Microbiota.感染后有症状和无症状小鼠之间的比较揭示了新的炎症途径和相关微生物群。
Microorganisms. 2022 Nov 30;10(12):2380. doi: 10.3390/microorganisms10122380.
本文引用的文献
1
Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients.嗜酸乳杆菌 CL1285 和干酪乳杆菌 LBC80R 专利益生菌配方治疗成人抗生素相关性腹泻和艰难梭菌相关性腹泻预防的剂量反应疗效。
Am J Gastroenterol. 2010 Jul;105(7):1636-41. doi: 10.1038/ajg.2010.11. Epub 2010 Feb 9.
2
Treatment with monoclonal antibodies against Clostridium difficile toxins.针对艰难梭菌毒素的单克隆抗体治疗。
N Engl J Med. 2010 Jan 21;362(3):197-205. doi: 10.1056/NEJMoa0907635.
3
Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.非达霉素：一种用于治疗艰难梭菌感染的大环内酯类抗生素。
Ann Pharmacother. 2010 Feb;44(2):352-9. doi: 10.1345/aph.1M351. Epub 2010 Jan 13.
4
Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality.加拿大与医疗保健相关的艰难梭菌感染：患者年龄和感染菌株类型与严重结局和死亡率高度相关。
Clin Infect Dis. 2010 Jan 15;50(2):194-201. doi: 10.1086/649213.
5
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.利福昔明：一种用于治疗肠道疾病的胃肠道选择性抗生素。
Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d.
6
Clostridium difficile testing algorithms: what is practical and feasible?艰难梭菌检测算法：什么是切实可行的？
Anaerobe. 2009 Dec;15(6):270-3. doi: 10.1016/j.anaerobe.2009.10.005. Epub 2009 Oct 22.
7
Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria.艰难梭菌毒素CDT诱导基于微管的突起形成并增加细菌的黏附。
PLoS Pathog. 2009 Oct;5(10):e1000626. doi: 10.1371/journal.ppat.1000626. Epub 2009 Oct 16.
8
Evidence-based review of probiotics for antibiotic-associated diarrhea and Clostridium difficile infections.抗生素相关性腹泻和艰难梭菌感染的益生菌治疗的循证评价。
Anaerobe. 2009 Dec;15(6):274-80. doi: 10.1016/j.anaerobe.2009.09.002. Epub 2009 Oct 13.
9
Fecal bacteriotherapy for recurrent Clostridium difficile infection.粪便细菌疗法治疗复发性艰难梭菌感染。
Anaerobe. 2009 Dec;15(6):285-9. doi: 10.1016/j.anaerobe.2009.09.007. Epub 2009 Sep 22.
10
High prevalence of tcdC deletion-carrying Clostridium difficile and lack of association with disease severity.艰难梭菌 tcdC 缺失株携带的高流行率及其与疾病严重程度之间缺乏关联。
Diagn Microbiol Infect Dis. 2010 Jan;66(1):24-8. doi: 10.1016/j.diagmicrobio.2009.08.015. Epub 2009 Sep 23.
Zotero 插件